• M. Rösler


Die chemische Bezeichnung für Propentofyllin lautet: (1-(5-Oxyhexyl)-3-methyl-1-7-propylxanthin) — C15H22N4O3, Molekulargewicht: 306,4.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andine P, Rudolphi KA, Fredholm BB, Hagberg H (1990) Effect of propentofylline on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. Br J Pharmacol 100: 814–818PubMedCrossRefGoogle Scholar
  2. DeLeo J, Toth L, Schubert P, Rudolphi K, Kreutzberg GW (1987) Ischemia-induced neural cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285). J Cereb Blood Flow Metab 7: 745–751PubMedCrossRefGoogle Scholar
  3. DeLeo J, Schubert P, Kreutzberg GM (1988) Protection against ischemic brain damage using propentofylline in gerbils. Stroke 19: 1535–1539PubMedCrossRefGoogle Scholar
  4. Fuji K, Hiramatsu M, Hayashi S, Kameyama T, Nabeshima T (1993a) Effects of propentofylline, a NGF synthesis stimulator, on alterations in muscarinic cholinergic receptors induced by basal forebrain lesions in rats. Neurosci Lett 150: 99–102PubMedCrossRefGoogle Scholar
  5. Fuji K, Hiramatsu M, Kameyama T, Nabeshima T (1993b) Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur J Pharmacol 236: 411–417PubMedCrossRefGoogle Scholar
  6. Goto M, Demura N, Sakaguchi T (1987) Effects of propentofylline on disorder of learning and memory in rodents. Jpn J Pharmacol 45: 373–378PubMedCrossRefGoogle Scholar
  7. Grome J, Hofmann W, Gojowczyk G, Stefanovich V (1996) Effects of a xanthin derivative, propentofylline, on cerebral blood flow and glucose utilization in the rat. Brain Res 740: 41–46PubMedCrossRefGoogle Scholar
  8. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss W-D (1993) Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 13: 526–530PubMedCrossRefGoogle Scholar
  9. Kindy MS, Bhat AN, Bhat NR (1992) Transient ischaemia stimulates glial fibrillary acid protein and vimentine gene expression in gerbil neocortex, striatum and hippocampus. Mol Brain Res 13: 199–206PubMedCrossRefGoogle Scholar
  10. Kittner B (1996) Propentofylline (HWA 285): a subgroup analysis of phase III clinical studies in Alzheimer’s disease and vascular dementia. In: Becker R, Giacobini E (eds) Alzheimer’s disease: from molecular biology to therapy. Birkhäuser, Boston, pp 361–365Google Scholar
  11. Kittner B, Rössner M, Rother M (1997) Clinical trials in dementia with propentofyllin. Ann NY Acad Sci 826: 307–316PubMedCrossRefGoogle Scholar
  12. Marcusson J, Rother M, Kittner B, Rössner M, Smith RJ, Babic T, Folnegovic-Smalc V, Möller HJ, Labs KH (1997) A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R. Dement Geriatr Cogn Disord 8: 320–328PubMedCrossRefGoogle Scholar
  13. McRae A, Rudolphi KA, Schubert P (1994) Propentofylline depresses amyloid and Alzheimer’s CSF microglial antigens after ischaemia. Neuroreport 5: 1193–1196PubMedCrossRefGoogle Scholar
  14. McRae A, Schubert P, Ogata T et al. (1996) Postischaemic glial responses and amyloid accumulation are modified by propentofylline: neuroprotective pharmacon for Alzheimer’s disease? Neurobiol Aging 17 [Suppl 4S]: 152CrossRefGoogle Scholar
  15. Mielke R, Kittner B, Ghaemi M, Kessler J, Szelies B, Herholz K, Heiss WD (1996) Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. J Neurol Sci 141: 59–64PubMedCrossRefGoogle Scholar
  16. Miki S, Miki Y (1991) Differential effects of propentofylline on the production of cytokines by peripheral blood mononuclear cells in vitro. Clin Ther 13: 747–753PubMedGoogle Scholar
  17. Minami M, Arai H, Takahashi T, Kimura M, Noguchi I, Suzuki T, Inoue R (1995) A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsychopharmacol Biol Psychiatry 19: 59–64PubMedCrossRefGoogle Scholar
  18. Miyashita K, Nakajima T, Ishikawa A, Miyatake T (1992) An adenosin uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus following transient forebrain ischemia. Neurochem Res 17: 147–150PubMedCrossRefGoogle Scholar
  19. Möller HJ, Maurer I, Saletu B (1994) Placebo-controlled trial of the xanthine derivative propentofylline in dementia. Pharmacopsychiat 27: 159–165CrossRefGoogle Scholar
  20. Nitta A, Ogihara Y, Onishi J, Flasegawa T, Furukawa S, Nabeshima T (1996) Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum. Eur J Pharmacol 307: 1–6PubMedCrossRefGoogle Scholar
  21. Noble S, Wagstaff A (1997) Propentofylline. CNS Drugs 8: 257–264CrossRefGoogle Scholar
  22. Park CK, Rudolphi KA (1994) Antiischaemic effects of propentofylline (HWA 285) against focal cerebral infarcation in rats. Neurosci Lett 178: 235–238PubMedCrossRefGoogle Scholar
  23. Rudolphi KA (1996) Propentophylline — preclinical data. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 355–359Google Scholar
  24. Saletu B, Möller H-J, Grünberger J, Deutsch H, Rössner M (1990) Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 24: 173–184PubMedCrossRefGoogle Scholar
  25. Schubert P, Banati RB, Dux E, Gehrmann J, Rudolphi K, Kreutzberg GW (1992) Reactive oxygen intermediates in microglial cells differentiating into brain macrophages: depression by propentofylline and relation to adenosin action. In: Krieglstein J, Oberpichler-Schwenk H (eds) Pharmacology of cerebral ischemia. WVG, STUTTGART, pp 461–467Google Scholar
  26. Schubert P, Ogata T, Ferroni S, McRae A, Nakamura Y, Rudolphi K (1996) Modulation of glial cell signaling by adenosine and pharmacological reinforcement. Mol Chem Neuropathol 28: 185–190PubMedCrossRefGoogle Scholar
  27. Schubert P, Ogata T, Rudolphi K (1997) Depression of TNF-alpha release from microglial cells by adenosine and propentofylline. J Cereb Blood Flow Metab 17 [Suppl 1]: S718Google Scholar
  28. Shimizu K, Ogino M, Yamaguchi N, Mitani S, Saito R, Kawase T, Toya S (1993) Propentofylline (HWA 285) inhibits the release of dopamine during trangient ischemia and modulates its metabolism in rat striatum. Neurosci Lett 158: 9–12PubMedCrossRefGoogle Scholar
  29. Shinoda I, Furukawa Y, Furukawa S (1990) Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem Pharmacol 39: 1813–1816PubMedCrossRefGoogle Scholar
  30. Si QS, Nakamura Y, Kataoka K (1997) Adenosine inhibits superoxide production in rat peritoneal macrophages via elevation of cAMP level. Immunopharmacology 36: 1–7PubMedCrossRefGoogle Scholar
  31. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshima T (1997) Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer’s disease. Behav Brain Res 83: 117–122PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • M. Rösler

There are no affiliations available

Personalised recommendations